Dr. Love has served as GBT’s president and chief executive officer since 2014 and as a member of its Board of Directors since September 2013. Dr. Love has broad leadership and management experience in the biotech/pharmaceutical industry.
Prior to GBT, he served as executive vice president, research and development and technical operations at Onyx Pharmaceuticals, where he played an instrumental role in initiating and completing several of Onyx’s first Phase 3 clinical trials. Prior to Onyx, he served as president, chief executive officer and chairman of Nuvelo, where he led growth of the company to a market capitalization of $1 billion. Prior to that, Dr. Love served as senior vice president, development, at Theravance.
Earlier in his career, Dr. Love held a number of senior management positions in medical affairs and product development at Genentech, where he served as chairman of Genentech’s Product Development Committee. As vice president, product development, Dr. Love oversaw the development strategy and execution leading to approvals of Rituxan®, Herceptin®, Xolair®, TNKase®, Raptiva® and Avastin®. Dr. Love served as a consultant in medicine in the Department of Cardiology at the Massachusetts General Hospital.
He currently serves on the boards of directors of Royalty Pharma and Seagen. He is also vice chair of the board of the Biotechnology Innovation Organization and a founding board member of Life Science Cares Bay Area. Dr. Love holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School. He completed a residency in internal medicine and a fellowship in cardiology at the Massachusetts General Hospital.